Psychiatry · Medical Literature
Implementing Evidence-Based Care for Alcohol Use Disorder.
Abstract
AbstractAlcohol use is a major contributor to morbidity and mortality, but most individuals with problematic alcohol use do not receive evidence-based care or accurate information about drinking. Recommendations on safe levels of alcohol consumption are rapidly evolving, with recent research finding health and social harms at levels well below traditional lower-risk drinking guidelines. Screening tools to identify alcohol use are widely available but infrequently used. Alcohol withdrawal management protocols have not kept pace with recent evidence highlighting the safety and benefits of benzodiazepine-sparing approaches. Similarly, despite clear evidence on the efficacy of psychosocial treatments and evidence-based pharmacotherapies (e.g., naltrexone) to treat alcohol use disorders, most individuals do not receive such treatment. Research also shows a lack of benefit and potential harm of routine use of antidepressants and other psychotropic medications commonly prescribed to individuals with alcohol use disorders. There is a critical opportunity for clinicians across specialties and healthcare systems to better identify and address alcohol use.
Clinical relevance
Alcohol use disorder (AUD) remains markedly undertreated across clinical settings, with the majority of affected individuals never receiving evidence-based pharmacotherapy or structured psychosocial intervention. This review addresses a critical practice gap by synthesizing evolving evidence on safe consumption thresholds, withdrawal management, and approved pharmacotherapies relevant to any specialty encountering patients with problematic alcohol use. The timely reassessment of lower-risk drinking guidelines and the signal of harm from routinely prescribed psychotropics make this article immediately actionable for psychiatrists, internists, and hospitalists alike.
Key findings
1. Recent evidence demonstrates that health and social harms from alcohol occur at consumption levels well below previously established lower-risk drinking guidelines, necessitating downward revision of 'safe' thresholds communicated to patients. 2. Validated screening tools for alcohol use disorder are widely available but remain infrequently deployed in clinical practice, representing a systemic failure in case identification. 3. Benzodiazepine-sparing protocols for alcohol withdrawal management have demonstrated safety and clinical benefit; however, current institutional protocols have not been updated to reflect this evidence. 4. Naltrexone and other evidence-based pharmacotherapies for AUD have clear efficacy data, yet the majority of patients with AUD do not receive these agents, indicating a substantial treatment gap. 5. Psychosocial treatments for AUD have demonstrated clear efficacy, but remain similarly underutilized across healthcare systems. 6. Routine use of antidepressants and other psychotropic medications commonly prescribed to individuals with AUD lacks evidence of benefit and carries evidence of potential harm, challenging widespread prescribing practices in this population.
Practice implications
Clinicians across all specialties should integrate validated alcohol screening instruments (e.g., AUDIT-C, AUDIT) into routine clinical encounters and counsel patients using updated, evidence-based lower-risk consumption thresholds that are considerably more conservative than traditional guidelines. For patients diagnosed with AUD, naltrexone (oral or extended-release injectable) should be offered as first-line pharmacotherapy in the absence of contraindications (e.g., concurrent opioid use, acute hepatitis), and the reflex prescription of antidepressants or other psychotropics solely for AUD management should be critically re-evaluated and avoided without a co-occurring independent indication. Inpatient teams managing alcohol withdrawal should adopt benzodiazepine-sparing protocols — such as symptom-triggered or phenobarbital-based approaches — where institutional infrastructure permits, in alignment with the current evidence base.